AVANDAMET Compared to Metformin Evaluation Trial (ACME): A 48-Week Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Tolerability of AVANDAMET to Metformin Monotherapy in Subjects With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Control on Submaximal Metformin.

Trial Profile

AVANDAMET Compared to Metformin Evaluation Trial (ACME): A 48-Week Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Tolerability of AVANDAMET to Metformin Monotherapy in Subjects With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Control on Submaximal Metformin.

Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Jul 2013

At a glance

  • Drugs Metformin; Rosiglitazone/metformin
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms ACME
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 20 May 2009 Actual initiation date changed from Apr 2003 to Jun 2003 as reported by ClinicalTrials.gov.
    • 09 Jun 2008 Actual end date Dec 2005 added as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top